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Diarrheal diseases impact millions of people worldwide every year.  Global 
mortality from diarrheal diseases is estimated between 4 and 6 million people per year 
according to the World Health Organization (WHO, 2003). Shigellosis and salmonellosis 
are two of the most important diarrheal diseases (Table 1.1). The gram-negative bacillus 
Shigella flexneri is a causative agent of shigellosis, a severe form of bacillary dysentery. 
According to the Centers for Disease Control and Prevention, there are approximately 
14,000 confirmed cases and perhaps 450,000 total cases of shigellosis occurring in the 
United States annually (CDC, 2008). This disease is endemic in the developing world 
with an estimated 1 million deaths per year, the majority of these being children under the 
age of five. Salmonella enterica serovar Typhimurium, one of the most common of the 
approximately 2500 serotypes of the genus Salmonella, is a gram-negative bacillus that 
causes nontyphoidal Salmonella  infection, which is a severe gastroenteritis in humans.  
The Centers for Disease Control and Prevention report an estimated 1.4 million cases of 
nontyphoidal salmonellosis annually in the United States, with 40,000 confirmed cases 









Table 1.1- Common Foodborne Bacterial 
Pathogens Causing Diarrheal Disease 
 In the United States 
 
Species of bacteria                               Incidence per 100,000 
Salmonella                                                                      7,444 
Campylobater                                                                  5,825 
Shigella                                                                           3,029 
Shiga toxin producing Escherichia coli                             513 
(0157) 
Shiga toxin producing Escherichia coli                             205 
(Non-0157) 
Yersenia                                                                              164 
Listeria                                                                               135 
Vibrio                                                                                 131 
 
 Table 1.1-Many bacterial pathogens cause diarrheal disease. While not all 
inclusive, this table lists some of the most common bacteria, in order of 








200 million to 1.3 billion annually. The death toll worldwide is approximated at 3 million 
each year (Coburn, Grassl, and Finlay, 2007).  
 Salmonella and Shigella infections represent major global public health burdens 
and substantial expenses to societies around the world. As strains are emerging with more 
resistance to antibiotics, vaccine development research for these pathogens has become 
crucial.  Both Salmonella and Shigella use a type III secretion system (TTSS) to invade 
host cells. The TTSS is made up of a basal body spanning the bacterial inner and outer 
membranes and an extracellular needle-like structure used to recognize and inject effector 
proteins into the host cell. The exposed portions of the TTSS could potentially be 
targeted for vaccine development. 
Historical Evaluation of Shigella 
The first account of the characterization and isolation of the causative agent of 
bacillary dysentery was made in Japan by Kiyoshi Shiga in 1897 while studying skeiri 
(dysentery) outbreaks. This work was done at the Institute of Infectious Disease on 36 
dysentery patients (Shiga, 1897). From the stool of these patients, he isolated a gram-
negative bacillus that fermented dextrose, did not ferment mannitol, and had a negative 
indole reaction (Niyogi, 2005). Shiga continued characterization of the bacillus and 
originally called it Bacillus dysenteriae (Shiga, 1906). This discovery led researchers 
Flexner, Boyd and Sonne, in the next 40 years, to define and place three additional 
species of this organism into the Enterobacteriaceae whose names were attributed to their 
researchers: S. flexneri, S. boydii, and S. sonnei into the genus Shigella (Hale, 1991). The 
genus was first recognized in Bergey’s Manual of Determinative Bacteriology in the 1930 
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edition and was officially accepted into the Congress of the International Association of 
Microbiologists in 1952 (Shigella Commission).  
With the establishment of the genus, defining and characterizing the mechanism 
of virulence became the focus of Shigella research in the 1950s.  The natural host range 
of shigellosis is limited to humans and other higher primates. In the latter part of the 
1950s and into the 1960s the first animal models began to emerge.  The corneal epithelia 
of guinea pigs were first successfully infected with Shigella spp. (Sereny test)(Sereny, 
1957). Soon following, it was established that Shigella spp. could be grown in cultured 
mammalian cells (Gerber and Watkins, 1961). High doses of Shigella have more recently 
been found to induce pneumonia and diarrhea in rats if presented nasally or rectally, 
respectively (Mallet et al., 1993) (Kamgang et al., 2005).   
 It was assumed until 1964 that the pathogenicity of Shigella was a result of the 
release of toxins while the bacteria were adhering to the surface of the epithelial cells of 
the intestine (Watkins, 1960). LaBrec et al. fed guinea pigs virulent strains of S. flexneri, 
and found they caused ulceration and penetration of the epithelial cells of the colon and 
lamina propria. This showed that in fact, it was through invasion of the colonic 
epithelium that Shigella accomplished pathogenicity. (LaBrec et al., 1964). 
 It was not until 1981 that the genetic basis for Shigella pathogenesis was 
discovered. Sansonetti and his colleagues detected the presence of a large plasmid in S. 
flexneri and S. sonnei.  The loss of this plasmid resulted in a loss of invasion in cultured 
mammalian cells (Sansonetti, 1981). All Shigella species have a large 200-kb virulence 
plasmid that contains the necessary genes that are required for invasion (Buchrieser et al., 
5 
 
2000).  Current research on Shigella is mostly focused on classifying and understanding 
the genes and proteins encoded on this plasmid.  
Historical Evaluation of Salmonella  
Salmonella organisms are gram-negative, rod-shaped bacteria that live in the 
intestines of many animal types and have evolved with their hosts to cause gastroenteritis 
and/or enteric fever (Ohl and Miller 2001). Accounts of Salmonella infection can be 
dated back to ancient times and are well described throughout history (Cunha, 2004).  
William Jenner clarified differences between typhus and typhoid based on epidemiology 
and symptomology in 1850 (Ellermeier and Slauch, 2006, 2006). Discovery of the Typhi 
serovar occurred in 1880, when Karl Eberth observed rod shaped organisms in the lymph 
and spleens of typhoid patients (Ellermeier and Slauch, 2006, 2006). In 1895 Theobald 
Smith, working under veterinarian Daniel E. Salmon at the USDA, isolated what became 
known as Salmonella  serovar Choleraesuis while looking for the causative agent of hog 
cholera (Ellermeier and Slauch, 2006, 2006). Now known as S. enterica, the organism is 
one of two species, the other being S. bongori, recognized as members of 
Enterobacteriaceae (Ellermeier and Slauch, 2006, 2006). 
The evolution of the genus has been delineated by a large number of investigators 
(Selander et al., 1996)(Baumler et al., 1998)(Edwards et al., 2002)(Porowollik et al., 
2002)(Chan et al., 2003) and can be summarized as follows: Salmonella diverged from E. 
coli around the time mammals first appeared, 120-160 million years ago.  Roughly 25-40 
million years ago, Salmonella obtained the Salmonella pathogenicity island 1 (SPI1) 
which encodes the type III secretion system involved the invasion of the intestinal 
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epithelium. At this time Salmonella was an intracellular pathogen affiliated with cold-
blooded vertebrates.  Salmonella subsequently acquired the Salmonella pathogenicity 
island 2 (SPI2), which has a type III secretion system that permits the organisms to 
colonize deeper tissues by surviving in macrophages.  The presence of the SPI2 is a 
defining characteristic of Salmonella spp. The seven subspecies of S. enterica (I, II, IIIa, 
IIIb, IV, VI, and VII) continued to evolve to fit their respective host niches. The ancestor 
of subspecies I, II, IIIb and VI developed the ability to phase shift between multiple 
structural subunits of flagella, the organism’s principal organ of motility.  This provided 
S. enterica with the ability to evade the host immune system further.  The subspecies I 
ancestor then acquired the ability to colonize warm-blooded animals, a major advance 
with marked repercussions for human health.  The subspecies I strains have subsequently 
evolved to colonize a variety of hosts.  Serovars such as Typhi are host specific, infecting 
only humans, however, serovar Typhimrium is less specific, and is able to colonize and 
cause disease in a variety of mammalian species. Salmonella serovar Typhimurium 
usually causes a self-limiting gastroenteritis in humans, but in mice it causes a systemic 
disease similar to typhoid fever. This species of Salmonella has therefore offered a 
valuable animal model for the study of these invasive pathogens and allowed genetic, 
biological, and biochemical analysis of its infection process (Brummell and Finlay, 
2000).  
Epidemiology of Shigella and Salmonella  
Shigellosis is exclusive to humans and other higher primates and infection is 
limited to the intestinal mucosa. Common symptoms can include watery diarrhea with 
mucus, fever, malaise, abdominal cramping, and ulceration of the mucosa resulting in 
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bloody stools (Niyogi, 2005). Symptoms exhibited are dependent on the species and 
quantity of the organisms ingested and additional complications can ensue including: 
septicemia, bacteremia, dehydration, hypoglycemia, uremic and hemolytic syndrome, and 
toxic megacolon (Phalipon and Sansonetti, 2007). Shigellosis is widespread throughout 
the world, infecting approximately 165 million individuals, 163 million of which inhabit 
developing countries. Over 1 million of these instances result in death, and children under 
the age of five account for over 600,000 deaths. This mortality rate due to dehydration 
and is exacerbated by malnutrition (World Health Organization). S. flexneri is most 
prevalent in developing nations, while S. sonnei is more common in industrialized 
countries (Niyogi, 2005).  In the United States the majority of outbreaks of Shigella affect 
children in day care facilities, migrant workers, travelers, custodial workers, homosexual 
men, and persons living in community homes and prisons (Niyogi, 2005). 
 Salmonella species can infect an extensive range of animals, and those infections 
can cause distinctive diseases in different hosts, producing gastroenteritis, typhoid fever 
and bacteremia. Certain infections can be host specific, although Salmonella serovar 
Typhimuruim has the ability to infect a wide range of animal hosts (Brummell and 
Finlay, 2000). Symptoms of gastroenteritis caused by Salmonella serovar Typhimurium 
include diarrhea, which can be watery or bloody, abdominal cramps, fever, nausea and 
vomiting. Salmonella can occasionally establish a localized infection or enter the blood, 
causing bacteremia. The bacteria often remain in the intestine and are excreted for several 
weeks (CDC). 1.4 million cases of nontyphoidal salmonellosis are annually reported in 
the United States. Worldwide estimates of nontyphoid Salmonella infection range from 
200 million to 1.3 billion. The death toll worldwide is estimated to be 3 million each year 
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(Coburn, Grassl, and Finlay, 2007). Salmonella can infect anyone, at any age, but elderly 
individuals, infants and those with a compromised immune system are the most at risk for 
a Salmonella infection (Wallis and Galyov, 2000). 
Both Shigella and Salmonella infections are acquired via the fecal-oral route and 
are primarily linked to poor hygienic practices and contaminated food or water. 
Overcrowding further contributes to outbreaks around the world.  The incidence of both 
infections is greater in the developing world for the above reasons and this compounds 
already existing problems in these underdeveloped nations (DuPont, 1989). 
Shigella flexneri and Salmonella  serovar Typhimurium-The Pathogens 
Species of Shigella and Salmonella belong to the family 
Enterobacteriaceae. (Kreig and Holt, 1984) (Haimovich and Venkatesan, 2006). Each 
organism is a gram-negative, faculatively anaerobic, oxidase negative, gastrointestinal 
pathogen with the ability to reduce nitrate and ferment glucose (Kreig and Holt, 1984).  
Shigella spp. can be differentiated serologically based on species-specific O-antigen 
components that each contain (Kreig and Holt, 1984). There are four species: A, B, C, 
and D belonging to S. dysenteriae, S. flexneri, S. boydii and S. sonnei, respectively 
(Niyogi, 2005). Shigella spp. are extremely infectious requiring as few as 10-100 
organisms to elicit shigellosis (DuPoint et al., 1989). 
The more serologically complicated Salmonella spp. are classified based on the 
Kauffman-White Classification Scheme. Salmonella is divided into 2 species, S. bongori 
and S. enterica, which are further divided into 2501 serovars based on surface antigens.  
O-antigen type is first determined followed by H-antigen expression classification. The 
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H-antigen expressed is dependent upon the flagellar protein type made and this can 
change through a process called phase variation. The phase, 1 or 2, denotes the 
organism’s motile or non-motile phenotype, respectively.  S. borgori is further divided 
into 21 serovars. S. enterica is  futher divided into 6 subspecies: I, S. enterica subsp. 
enterica,(1,478 serovars); II, S. enterica subsp. salamae, (498 serovars); IIIa, S. enterica 
subsp. arizonae, (94 serovars); IIIb, S. enterica subsp. diarizonae, (327 serovars);IV, S. 
enterica subsp. houtenae,(71 serovars); and VI, S. enterica subsp. indica. (12 serovars) 
(Centers for Disease Control and Prevention, 2006). 
Shigellosis and salmonellosis are self-limiting infections with symptoms lasting 
5-7 days or longer if untreated (Hueck, 1998) (Bullock et al., 2006). If treated with 
antibiotics, the duration of symptoms is lessened and the period that the organisms are 
shed following recovery is shortened, however, as long as the individual is shedding the 
organisms, the diseases can easily be spread (Sur, 2004) (Brands, 2006). Individuals with 
symptoms of diarrhea for salmonellosis and shigellosis are most responsible for 
transmission of the disease. Poor sanitation and hygiene practices and contaminated food 
or water sources are common causes of outbreaks of these diseases (Niyogi, 2005) 
(Brands, 2006).  Oral antibiotics are the most preferred means of treatment for Shigella 
and Salmonella infections. Unfortunately, due to the ability of bacteria to adapt and 
overcome host defenses, there has been an emergence of strains that have acquired 
antibiotic-resistance, which is limiting the number of drugs available for treating each 




Genetics of Virulence 
All species of Shigella harbor a large virulence plasmid.  Genes encoded on this 
plasmid and those of the pathogenicity islands located on its chromosome, provide the 
bacteria with antibiotic resistance, iron acquisition and proteases (Schroeder and Hilbi, 
2008). Shigella virulence and its ability to invade human intestinal cells are made 
possible by genes on the 200-kb virulence plasmid, which contains approximately 100 
genes (Maurelli et al., 1985) (Yoshikawa et al., 1988).  Genes included on this plasmid 
are required for bacterial uptake and propagation within the colonic epithelium 
(Wantanabe, 1990). The type III secretion system facilitates bacterial uptake and is 
encoded by the 31-kb entry region of the virulence plasmid (Schroeder and Hilbi, 2008). 
This entry region also contains the Mxi-Spa and Ipa-Ipg operons, which encode the type 
III secretion apparatus, and its secreted effectors, and the translocators IpaA, IpaB, IpaC, 
IpaD along with the molecular chaperone IpgC (Espina, et al., 2006) (Figure 1.1). If this 
virulence plasmid is not present, Shigella are not infectious (Yoshikawa, et al., 1988). 
Noninvasive E. coli strains ahve been shown to become invasive upon receiving the 
Shigella virulence plasmid (Sansonetti 1982).  
  There are four categories of genes in the entry region of the virulence plasmid, 
which are distinguished based on their functions (Schroeder and Hilbi, 2008). Ipa 
(invasion plasmid antigen) genes function as effector and translocator proteins secreted 
by the TTSA make up the first group and these are involved in the cytoskeletal  
















Figure 1.1-The type III Secretion System of Shigella flexneri 
The TTSS is made up of a basal body; spanning the inner and outer 
bacterial membrane, a needle complex; facilitating injection of effector 
proteins, and a pore complex which allows host cell recognition and 
translocation of effectors into host cells (Schroeder and Hilbi, 2008).  
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 rearrangements, and the cell membrane ruffling which result in bacterial uptake. The 
structural proteins Mxi (membrane expression of Ipa proteins) and Spa (surface 
presentation of Ipa antigens) make up the second group (Espina et al., 2006) (Schroeder 
and Hlbi, 2008). Mxi and Spa structural protein polymers comprise the basal body and 
needle of the TTSA (Espina, et al., 2006).  Transcriptional activators control expression 
of the early and late entry region genes, and these make up the third group. The molecular 
chaperones then fall into the fourth group, and they function to protect effector and 
translocatorproteins while they are stored in the cytoplasm prior to secretion (Schroeder 
and Hilbi, 2008).  
 The invasion of human cells and subsequent intracellular replication by 
Salmonella is multifaceted.  There are approximately 200 genes including those on the 
five chromosomal pathogenicity islands (SPI-1 to SPI-5) on the Salmonella  serovar 
Typhimurium chromosome that are essential for virulence.  SPI-1 and SPI-2 encode two 
of the type III secretion systems that facilitate invasion by Salmonella species. SPI-1 is 
necessary for intestinal epithelium invasion and SPI-2 is required for survival within 
macrophages (Haimovich and Venkatesan 2006). SPI-1 encodes over 30 proteins, 
including those that comprise the TTSS-1 and its secreted effectors. Salmonella invasion 
proteins are encoded by the Sip/Sic operon on SPI-1 (Galan, 1996) (Hueck, 1998). 
Secreted proteins SipA, SipB, SipC and SipD and the molecular chaperone, SicA are 
homologues to Shigella Ipa proteins and IpgC., Each of the four required effectors and 
the chaperone function in host cell invasion in the same way their Shigella homologues 
(Espina, et al., 2006). Salmonella serovar Typhimurium mutants deficient in SPI-1 are 
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incapable of invading M cells and other intestinal epithelial cells, stressing the necessity 
of SPI-1 genes in intestinal colonization (Galan, 1996) (Hueck, 1998).  
Following invasion of host cells, SPI-2 genes are expressed and are necessary for 
intracellular survival of Salmonella in both epithelial cells and macrophages (Haimovich 
and Venkatesan 2006). SsrA-SsrB is encoded by SPI-2 and regulates the TTSS-2 which 
is required for intracellular survival and subsequent replication within the host. Mutants 
lacking SPI-2 genes resulted in a reduction of virulence and the inability to colonize the 
spleens of infected animals (Anthea, Detweiler and Falkow, 2000). It is believed that the 
systemic infection in mice caused by Salmonella infection is reliant upon its ability to 
colonize and replicate within macrophages, and this is one of the traits setting apart 
Salmonella infection from gut-confined shigellosis (Haimovich and Venkatesan 2006).  
Cellular Invasion by Shigella flexneri and Salmonella serovar Typhimurium 
After ingestion, Shigella flexneri is protected from the stomach due to its high 
acid tolerance. It then facilitates its way to the large intestine using as set of enterotoxins 
called sen and set (Kotloff, et al., 2000). In the large intestine, S. flexneri invades the 
colonic epithelium (Sur, 2004). . Invasion requires that the organism reach the basolateral 
face of the epithelial cells. Once in the large intestine, S. flexneri is taken up in vacuoles 
by microfold cells (M cells) via macropinocytosis in the colon (Owen, 1986) (Wassef, 
1989). The organisms then escape the vacuole into the cytosol, and travel to underlying 
macrophages that are associated with M cell-associated lymphoid follicles (Sansonetti, et 
al., 1996). Shigella is transcytosed into an intraepithelial pocket by M cells, (Schroeder 
and Hilbi, 2008) where it is then taken up by a resident macrophage, which is triggered to 
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undergo apoptosis. This allows escape of the pathogens to the basal side of the 
epithelium. Death of the macrophage is initiated via a caspase 1-dependent pathway, and 
this leads to the release of the proinflammatory cytokines, Interleukin-1β (IL-1β) which 
triggers inflammation in the lower intestine, and Interleukin-18 (IL-18) which activates 
NK cells. Production of IL-8 follows this inflammation trigger, which recruits 
polymorphonuclear cells. PMNs initiate tissue damage and allow more bacteria to bypass 
the M cells and reach the submucosa via destabilization of the epithelial lining 
(Schroeder and Hilbi, 2008) (Sansonetti, 2000). The tight junctions of epithelial cells are 
also altered and loosened, exacerbating the initial invasion of S. flexneri. All of this leads 
to the bloody diarrhea that the organism is known for (Schroeder and Hilbi, 2008). After 
crossing the epithelial barrier and inducing ingestion by the epithelial cells of the colon, 
Shigella uses actin-based motility to move through the cytoplasm laterally from cell to 
cell (Mounier et al., 1992).  This further enhances inflammation and ulceration of the 
mucosa in the colon. This is attributed to shigellosis, but it is actually a result of the 
host’s own immune response to the infection (Wassef et al., 1989) (Islam et al., 1997). 
The goal of Shigella flexneri is to replicate within its host cell’s cytoplasm, and invade 
neighboring cells by spreading laterally through the colonic epithelium. This intracellular, 
replicative niche of S. flexneri is also what protects the organism from the extracellular 
immune system components (Schroeder and Hilbi, 2008). 
 Salmonella serovar Typhimurium is not so resistant to the acid from the stomach 
and thus a much higher inoculum is required for invasion unless there is a deficiency of 
stomach acid, which can be caused by various factors including improper nutrient 
absorption, stress or alcohol consumption (Jones and Falkow, 1996) (Hersh, 1999). 
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Salmonella serovar Typhimurium achieves invasion of the colonic epithelia by the same 
mechanism as S. flexneri, but it does not necessarily stop there. The goal of Salmonella 
serovar Typhimurium is to penetrate the mucosal barrier and interact with the cells of the 
immune system (Bowe, Lipps, Tsolis, Groisman, Heffron, and Kusters, 1998). 
Salmonella serovar Typhimurium has adapted mechanisms to survive and replicate 
within the vacuoles of these cells. In particular, infection of macrophages allows 
Salmonella serovar Typhimurium to disseminate beyond the mucosal surface to initiate 
systemic infection (Brumel and Finlay, 2000). Following invasion of host cells, 
Salmonella serovar Typhimurium becomes localized in the Salmonella-containing 
vacuole (SCV) within which the organism replicates and is protected from stomach acid 
and the immune system.  It eventually lyses the host cell and escapes to the extracellular 
environment to infect its next host (Fields, Swanson, Haidaris and Heffron, 1986). This 
ability to survive and replicate within phagocytic cells, such as the macrophage, is 
another example of what differentiates Salmonella infections in humans from gut-
contained shigellosis (Haimovich and Venkatesan, 2006). 
The Type Three Secretion System 
  Bacteria carry secretion systems as part of their natural functions.  Many gram-
negative bacterial pathogens use needle-like, highly homologous secretion systems to 
manipulate host cell signals and eventually transport effector molecules or virulence 
factors into targeted eukaryotic host cells (translocation) or possibly into the extracellular 
environment (secretion). There are currently six recognized classed of bacterial secretion 
systems (numbered I to VI). Shigella and Salmonella spp. possess type III secretion 
systems and their invasion of human cells is dependent on the translocation of effector 
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proteins that manipulate a targeted host’s cytoskeleton, thereby inducing membrane 
ruffling and subsequent bacterial uptake.  Salmonella serovar Typhimurium also harbors 
a second type III secretion system which facilitates its survival and replication within 
host cell phagosomes (Monack, Raupach, Hromockyj and Falkow, 1996). Additionally, 
S. flexneri and Salmonella serovar Typhimurium are capable of inducing apoptosis of 
macrophages, which is facilitated by their type III secretion systems and which allows 
their escape after crossing the intestinal epithelium (Ruckdeschel, et al., 1997). 
 The type III secretion system is made up of a basal body that spans the inner and 
outer membranes of the bacterium and an extracellular needle complex that bacteria use 
as a molecular syringe to deliver effectors directly into the target cell’s cytoplasm and 
promote bacterial uptake or host cell killing (Hueck, 1998)(Cornelis, 2006) (See Fig. 1.1 
and 1.2) The needle is a polymer that is approximately 50 nm long, 7 nm wide, and 
contains an inner channel with a diameter of about 2.5 nm (Epler et al., 2009).  Type III 
secretion is contact dependent and is an ATPase-driven system. The ATPase elaborates 
protein unfolding, chaperone release, and transmembrane transport of the substrate 











Figure 1.2. Components of the TTSS 
An overview of the TTSS including: the basal body, spanning the inner and outer 
membrane; extracellular needle; and tip complex for Salmonella (Sip, Prg and Inv 




The Ipa and Sip Proteins 
Shigella and Salmonella use closely related type of type III secretion systems to 
deliver effector proteins into host cells. The homologous proteins that make up the needle 
complex for Shigella and Salmonella are MxiH and PrgI, respectively. Due to their 
fundamental role in surface exposure and virulence, they are attractive vaccine 
component candidates (Darboe, et al., 2006). Effector proteins that are secreted and 
translocated during interaction of Shigella with the host cell are IpaD, IpaB, IpaC, IpaA 
and the molecular chaperone IpgC. Based on nucleotide sequencing Salmonella have 
genes that encode for homologues of these five Shigella proteins used in their own TTSS: 
SipD, SipB, SipC, SipA and SicA, respectively, which assemble and function in the 
TTSS in the same way and are required for invasion (Kaniga, Trollinger and Galan, 
1995). Salmonella further diverges from Shigella in that it uses a second TTSS to survive 
and replicate within the macrophage to induce systemic infection (Monack, Raupach, 
Hromockyj and Falkow, 1996). 
To promote bacterial uptake, Shigella exploits secreted effector proteins that 
facilitate entry into the target cell and seize control of host cytoskeletal proteins. IpaD sits 
at the tip of the MxiH needle apparatus, where it senses environmental signals, initiates 
secretion induction, (Espina et al., 2006) and is an important secretion substrate in 
Shigella type III secretion. As IpaD binds and thereby senses intestinal bile salts, IpaB is 
secreted and recruited to the tip of the TTSA needle (Stensrud et al., 2008). It is at this 
point that the TTSS of Shigella is equipped for full induction of type III secretion. 
Following host cell contact, additional secreted effectors include the final translocator 
protein, IpaC which is recruited to the needle tip and is secreted into the host cell 
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membrane (Epler et al., 2009) (van der Goot et al., 2004). Studies in our lab have shown 
that the presense of bile salts, found in high concentrations in the small intestine, induces 
the secretion of IpaB and leads to the co-localization of IpaB and IpaD at the distal tip of 
the TTSA needle (Olive et al., 2007). This is said to be a priming step that prepares the 
needle for interaction with the host cell via cholesterol binding by IpaB (Olive, 2007) 
(Hayward et al., 2005). 
 The molecular chaperone IpgC (invasion plasmid gene) binds to IpaB prior to 
IpaB secretion by S. flexneri (Birket et al., 2007), thus preventing aggregation of IpaB 
within the bacterial cytoplasm, and its binding to IpaC, the final translocator protein at 
the TTSA needle tip (Menard et al., 1994) (Page et al., 1999) (Lunelli et al., 2009).  
Association between IpaB and IpgC has been shown to maintain the pre-secretion state of 
IpaB for its consequent passage through the needle of the TTSS (Menard et al., 1994) 
(Page et al., 1999). IpgC additionally acts as a chaperone for IpaC, the final 
translocator/effector protein. IpaC joins with IpaB to form a translocon pore component 
(Menard et al., 1994) (Page et al., 1999) and it is involved with host cell signaling (Tran 
Van Nhieu et al., 1999).   
The preliminary proteins secreted by the Salmonella Pathogenicity Island-1 (SPI-
1) TTSS are called Sips (Salmonella invasion proteins), and are homologous to Shigella 
proteins and function in invasion of the host cell and secrete effectors in the same manner 
(refer to Figure 1.2). Invasion by Salmonella requires SipD, SipB, SipC, and the 
molecular chaperone SicA, just as homologues, IpaD, IpaB, IpaC,and IpgC, respectively, 
are essential for Shigella invasion (Kaniga, Trollinger and Galan, 1995)(Kaniga, Tucker, 
Trollinger and Galan, 1995). SipB and SipC are secreted through the Salmonella TTSA 
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and form a translocon pore in the host membrane (Cossart and Sansonetti, 2004) (Galan, 
2001). As with the Shigella homologues, mutations in Salmonella proteins SipD, SipB, 
SipC, and SicA individually, prevent the SipB/SipC translocon from inserting into the 
host cell membrane, which is why each protein is required for translocon formation 
(Cossart and Sansonetti, 2004). 
 IpaB and SipB are important to study because they have several functions that are 
crucial to Shigella and Salmonella pathogenesis.  Both serve as secreted effector proteins, 
both regulate type III secretion, and both function as structural proteins in the formation 
of the translocon pores that form in the host cell membrane (Schroeder and Hilbi, 2008).  
After initially crossing M cells, S. flexneri and Salmonella serovar Typhimurium secrete 
IpaB and SipB, respectively, to induce apoptosis via a caspase1-mediated pathway and 
allow escape from the macrophage (Hilbi et al., 1998) (Hersh et al., 1999).  This 
apoptotic (pyroptotic) pathway results in the massive release of IL-1β, which provides the 
signal for induction of the inflammatory processes that lead to the inflammation and 
tissue damage that give rise to symptoms (Sansonetti, 2000). IpaB and SipB also serve to 
control effector regulation, as do IpaD and SipD (Menard et al., 1994) (Galan, 2001). 
IpaB and SipB are also each a component of the two-part translocon pore that is inserted 
into the host cell membrane after intial contact.  The other translocon components for 
each are IpaC and SipC (Schroeder and Hilbi, 2008).  IpaD and SipD allow this pore to 
remain in contact with the TTSA needle tip (Schroeder and Hilbi, 2008) (Kaniga, 
Trollinger and Galan, 1995)(Kaniga, Tucker, Trollinger and Galan, 1995), thus forming a 
conduit through the membrane to the host cell’s cytoplasm, channeling direct injection 
and secretion of later effectors from the bacterium to the host cell’s cytoplasm (Menard et 
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al., 1994) (Zychlinsky et al., 1994) (Blocker et al., 1999)(Kaniga, Trollinger and Galan, 
1995)(Kaniga, Tucker, Trollinger and Galan, 1995). 
Research Focus 
Shigellosis and salmonellosis are two of the most common diarrheal diseases in the 
world, causing over 4 million deaths per year with the majority of these being in children. 
The development of vaccines for these diseases is dependent on overcoming several 
significant barriers. There is currently no vaccine for Salmonella serovar Typhimurium or 
S. flexneri available for use in humans. This problem is confounded further by the need 
for a vaccine that is safe and effective in children. Development of vaccines for 
salmonellosis and shigellosis is also difficult due to the massive number of serovars of 
the pathogen. Vaccine development is hampered due to the lack of an appropriate animal 
model. The current mouse model relies upon a pulmonary induced Shigella infection. 
This is much different than the gastroenteritis that occurs in humans. The mouse, 
employed as a model for human typhoid fever, develops a systemic disease when infected 
with Salmonella serovar Typhimurium, with no diarrhea (Santos et al., 2003). 
Constructing a vaccine that is applicable in the developing world has also been a 
challenge because of differences in the gut flora and nutrition status as compared to the 
developed world. There are also concerns with the use of a live-attenuated vaccine. It is 
not advantageous due to the serotype specificity of these vaccines and the need for a 
vaccine that can be safely administered to children.  
Formulating a vaccine that is protective against Shigella and Salmonella 
infections in mice is the initial step needed for development of a practical and successful 
vaccine in humans. This research is focused on the assessment of the translocators of the 
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type three-secretion system as protective antigens against Shigella and Salmonella 
infection in respective mouse models. My hypothesis is that the exposed parts of the 
Shigella and Salmonella TSSAs can be targeted for development of an effective subunit 
vaccine. In Shigella, this means targeting MxiH (needle), IpaD (tip protein), and IpaB 
(tip-associated translocator protein) and in Salmonella homologues, PrgI (needle), SipD 












Materials and Methods 
 
Reagents and Buffers 
 
Coomassie Blue Protein Gel Stain 
250 mL methanol 
1.25 g Coomassie brilliant blue 
75 mL acetic acid 
175 mL diH2O 
 
8X His-Tag Binding Buffer 
2.72 g imidazole 
237 g NaCl 
19.36 g Tris 
Adjust to 1.00 L with diH20 
 
4X His-Tag Charge Buffer 
52.56 g NiSO4 
Adjust to 500 mL with diH2O 
 
4X His-Tag Elution Buffer 
136 g imidazole 
58.44 g NaCl 
4.84 g Tris 
Adjust to 500 mL with diH2O 
pH to 7.9 
 
4X His-Tag Strip Buffer 
74.4 g EDTA 
58.44 g NaCl 
4.84 g Tris 
Adjust volume to 500 mL with diH2O 
pH to 7.9 
24 
 
8X His-Tag Wash Buffer 
5.44 g imidazole 
117 g NaCl 
9.68 g Tris 
Adjust volume to 500 mL with diH20 
pH to 7.9 
 
Luria-Bertani Broth (LB) 
25.0 g LB broth 
1.00 L diH2O 
 
Luria-Bertani Agar (LB) 
40.0 g LB agar 
1.00 L diH20 
 
10X Phosphate Buffered Saline (PBS) 
85.0 g NaCl 
10.7 g sodium phosphate, dibasic 
3.90 g sodium phosphate, monobasic 
1.00 L diH2O 
 
12% SDS-PAGE Separating Gel 
3.00 mL diH20 
2.50 mL 1.5 M Tris-HCL, pH 8.8 
100 μL 10% SDS 
4.00 mL 30% Bis:Acrylamide 
 
15% SDS-PAGE Separating Gel 
2.50 mL diH20 
2.50 mL 1.5 M Tris-HCL, pH 8.8 
100 μL 10% SDS 
5.00 mL 30% Bis:Acrylamide 
 
5% SDS-PAGE Stacking Gel (2) 
2.85 mL diH2O 
1.25 mL 0.5 M Tris-HCl, pH 6.8 
50.0 μL 10% SDS 
1.00 mL 30% Bis:Acrylamide 
 
SDS-PAGE Running Buffer 
2.42 g Tris 
14.41 g glycine 
10.0 mL SDS 





1X Sodium Phosphate Dialysis Buffer (NaP buffer) 
20 mL .5 M NaP 
8.77g NaCl 
5 mL OPOE 
Adjust to 1 L with 1X PBS 
 
10 mM Histidine buffer 
2.1 g Histidine 
8.77 g NaCl 
in 1L H20 
 
1x PBS + 0.5% Tween 
1L 10x PBS 
5 mL Tween 20 
added to 9L di H20 
 
10%NFDM 
20 g Best Choice Non-fat dry milk 
200mL PBS or PBS + 0.5% Tween 
Mix on stir plate for 40 minutes 
 
TMB Peroxidase Substrate  
TMB peroxidase substrate- 0.4 g/L 3,3',5,5'- tetramethylbenzidine. 
Peroxidase Substrate Solution B - 0.02% H2O2 in Citric Acid buffer. 
 
Peroxidase-Labeled Antibody To Mouse IgG 
Affinity purified antibody isolated from a pool of serum from goats immunized with 
purified mouse IgG was labeled with peroxidase by the periodate method by KPL. 
 
Phosphoric Acid Stop Solution 
55.2 mL H3PO4 
944.8 mL diH20 
 
Construction/Production of Recombinant Proteins 
 mxiH, ipaB, ipaD, prgI, sipB and sipD were subcloned from the pUC-based 
plasmid pHS2 into pET15b.  The resulting constructs were then transformed into Nova 
Blue E. coli.  Transformants were screened with T7 promoter and terminator primers.  
Plasmids containing inserts were then purified using a QIAGEN QIAquick
TM
 plasmid 
purification kit.  ipaB/plasmid and ipgC/pACYC were then co-transformed, and 
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sipB/plasmid and sicA/pACYC were co-transformed, both into Tuner (DE3) E. coli. 
Transformations were plated on LB plates containing either ampicillin for bacteria 
containing genes on pET15b or ampicillin and chloramphenicol for those containing 
genes on both pET15b and pACYC plasmids.  Several colonies were selected and frozen 
as permanent stocks.  A loop of the permanent stock was resuspended in 50 mL of LB 
and grown overnight at 37 °C with shaking.  The 50 mL culture was then divided evenly 
between four liters of LB, each containing either 100 μg/mL ampicillin or 100 μg/mL 
ampicillin and 25 μg/mL chloramphenicol. Cultures were grown to mid-log phase (OD600 
= 0.6) and the protein expression was induced using 0.5 M isopropyl-thio-2-D-
galactopyranoside (IPTG).  Induced cultures were grown for an additional three hours.  
The bacteria were then collected by centrifugation and resuspended in 40 mL/L of 
culture, with 1X His-tag binding buffer.  The bacterial suspension was frozen at –80°C. 
Ni+ Affinity Protein Purification of His-Tag Containing Proteins 
 Frozen bacterial suspensions were thawed, sonicated and clarified by 
centrifugation for 15 minutes at 10,000 x g.  Three mL of iminodiacetic acid Sepharose 
resin were washed with five column volumes (CV) of distilled water.  The resin was 
charged with three CV of 1X His-tag charge buffer and then five CV of 1X His-tag 
binding buffer.   Clarified supernatants of IpaD and SipD were applied to the column, 
which was washed with an additional five CV of binding buffer.  Non-specifically bound 
proteins were removed with five CV of 1X His-tag wash buffer and bound proteins were 
then eluted in three CV of 1X His-tag elution buffer.  Fractions were collected and 
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to 
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check for presence of protein.  The resin was stripped with three CV of 1X His-tag strip 
buffer and stored at 4°C. 
Ni+ Affinity Protein Purification of His-Tag Containing Proteins with OPOE 
 Frozen bacterial suspensions were thawed, sonicated and clarified by 
centrifugation for 15 minutes at 10,000 x g.  Three mL of iminodiacetic acid Sepharose 
resin were washed with five CV of distilled water.  The resin was charged with three CV 
of 1X His-tag charge buffer and then five CV of 1X His-tag binding buffer.  Clarified 
supernatants of IpaB and SipB were applied to the column; three mL of binding buffer + 
1% n-octyl-poly-oxyethlene (OPOE) was added.  The column was allowed to rock 
overnight in a cold room at 4°C.  Non-specifically bound proteins were removed with 
five CV of 1X His-tag wash buffer with 1% OPOE and bound proteins were then eluted 
in three CV of 1X His-tag elution buffer with 1% OPOE.  Fractions were collected and 
analyzed by SDS-PAGE gel to check for presence of protein.  The resin was stripped 
with three CV of 1X His-tag strip buffer and stored at 4°C for future use. 
Ni+Affinity Protein Purification of His-Tag Containing Proteins with 6M Urea 
 Frozen bacterial suspensions were thawed, sonicated, homogenized and clarified 
by centrifugation for 15 minutes at 10,000 x g.  Three mL of iminodiacetic acid 
sepharose resin were washed with five CV of distilled water.  The resin was charged with 
three CV of 1X His-tag charge buffer and then five CV of 1X His-tag binding buffer.  
Clarified supernatants of MxiH and PrgI were applied to the column; three mL of binding 
buffer + 6M Urea was added. Non-specifically bound proteins were removed with five 
CV of 1X His-tag wash buffer with 6M urea and bound proteins were then eluted in three 
CV of 1X His-tag elution buffer with 6M urea.  Fractions were collected and analyzed by 
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SDS-PAGE gel to check for presence of protein.  The resin was stripped with three CV of 
1X His-tag strip buffer and stored at 4°C for future use. 
Dialysis of Proteins Following Purification 
 Proteins were placed in a Thermo Scientific Slide-A-Lyzer dialysis cassette.  All 
dialysis steps were done at 4°C.  Cassettes were dialyzed against 500 mL of 10mM 
Histidine or 1x PBS dialysis buffer for IpaD and SipD and 500 mL of 10mM Histidine 
buffer + 1% OPOE or 1x PBS +1% OPOE for IpaB and SipB, overnight at 4°C, stirring 
constantly. MxiH and PrgI were placed in dialysis tubing and dialyzed overnight at 4°C, 
stirring constantly in 1L of 1x PBS + 4M urea and continued to dialyze stepwise, 
decreasing the concentration of urea by ½ each day. This was done until buffer contained 
only 1x PBS. Purified proteins were removed from dialysis were placed into a 1.5 mL 
Eppendorf tube and stored at 4°C. 
The concentration of each protein was then determined by the Beer-Lambert Law: 
(A=εbc); where A is the absorbance at 280nm, ε is the extinction coefficient of the 
protein, b is the path length and C is concentration. The extinction coefficient measures 
the amount of light a protein absorbs at a given wavelength. From the amino acid 
composition of the protein and the known molar extinction coefficients of Tyrosine (Tyr), 
Tryptophan (Trp), and Cysteine extinction coefficients of native proteins can be 
calculated. The formula for this calculation is: 
Extinction coefficient (Protein) = (Number of Tyr)*(Extinction coefficient of Tyr) + 
(Number of Trp)*(Extinction coefficient of Trp) + (Number of Cysteines)*(Extinction 
coefficient of Cysteine)  
ε (prot) = (#Tyr)(5,500) + (#Trp)(1,490) + (#Cysteine)(125) 
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ProtParam is a tool in ExPASy Proteomics Server used by our lab to calculate the 
extinction coefficient. Using the native protein sequence provided, the program calculates 
the extinction coefficient of proteins based on their amino acid composition. Using the 
equation below and by solving for c, the concentration for each protein was calculated by 
dividing the absorbance by the extinction coefficient (Table 2.1)(Gasteiger, et al., 2005). 
When multiplied by the molecular weight of the protein, the product is the protein 
concentration in mg/mL. 
































Table 2.1 The proteins used in Experiment 2, their molecular weights, and extinction 
coefficients. Absorbance at A280, is divided by the extinction coefficient and 
concentration is calculated based on Beer-Lambert Law (A=εbc). Multiplying the 
concentration (C) by the molecular weight of the protein yields the protein’s 











Calculation of Protein Concentrations 









MxiH 10,330 9,970 
IpaD 36,634 36,900 
IpaB 64,349 11,460 
PrgI 8,856.9 12,950 
SipD 37,112 38,390 
SipB 62,451 16,960 
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Animal Protocols  
 Prior to this current study, Dr. Wendy Picking and Dr. Julian Kissman conducted 
Experiment 1. These preliminary trials were used to determine the 50% mouse lethal dose 
(LD50) and evaluate Salmonella proteins PrgI and SipD along with Shigella proteins 
MxiH and IpaD, as potential protective antigens. This research was incorporated in the 
development of Experiments 2 and 3. Six to eight-week old female Balb/c mice (Mus 
musculus) were housed in groups of five in microisolator cages in the OSU animal 
facility. Animals were fed and watered ad libidum and they were ear-tagged for 
identification and weighed initially.     
There were 300 mice involved with Experiment 2. Adjuvants used in Experiment 
2 are listed in Table 2.2. Flow charts illustrating Experiment 2 are depicted in Figures 
2.1-2.4. Each chart follows a basic procedural outline and includes: number of mice per 
group, group classification, adjuvants used, bleeding schedule, immunization days, 
challenge, and monitoring of animals post challenge. Groups were established for 
intramuscular and intranasal vaccines. One hundred and forty mice were grouped for 
intramuscular vaccines and 160 mice were grouped to receive intranasal vaccines. Each 
animal group was comprised of ten mice (n=10). Classification of these groups was based 
on the vaccine components for the group. Proteins used for Salmonella vaccines were 
PrgI, SipD and SipB. Shigella vaccines incorporated the proteins MxiH, IpaD and IpaB. 
Intramuscular immunizations were formulated with Freund’s adjuvant, Freund’s 
Incomplete Adjuvant, and Monophosphoryl lipid A (MPL). Intranasal immunizations 
were formulated with cholera toxin adjuvant, MPL and MPL with chitosan. 
Intramuscular immunizations were administered on days 0, 14 and 28. Intranasal 
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immunizations were given on days 0, 14, 28 and 42. Mice were bled via facial vein two 
days prior to all immunizations and challenge. Mice receiving Shigella vaccines were 
challenged intranasally with Shigella strain 2457T. Mice that were given Salmonella 
vaccines were challenged ororgastrically with Salmonella strain SL1344. All animals 
were challenged 28 days after receiving the final immunization. Mice were monitored for 
up to two weeks post challenge. During this period, mice were scored based on health 
and weights were recorded daily. Mice losing 25% of initial body weight were promptly 
euthanized by cervical dislocation. All survivors were euthanized on day15 day post 






























Table 2.2. Adjuvants used in Experiment 2 for intramuscular (IM) and intranasal (IN) 
vaccinations. AH, CFA , IFA and MPL were used in intramuscular immunizations with 
and with out antigens. CT, MPL and Chitosan formulated with and without antigens were 
components of intranasal immunizations. All adjuvants for Experiment 2 were provided 








Adjuvants used for Experiment 2 
Alhydrogel-Aluminum hydroxide (AH) -10 mg/mL                          [IM] 
Cholera toxin (CT) -1mg/mL                                                              [IN] 
Freund’s (CFA)-1mg/mL                                                                     
[IM] 
Incomplete Freund’s (FA) -1mg/mL                                                    
[IM] 
Monophosphoryl lipid A- (MPL) -1mg/mL                           [IM and IN] 
Chitosan -2mg/mL                                                                               [IN] 
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Flow Charts for Experiment 2 
 
                             
Figure 2.1. 70 mice were given intramuscular immunizations on days 0,14 and 28. Mice were bled 2 days prior to 
immunizations and orogastric challenge with S. typhimurium strain SL1344.  Groups of 10 mice were given vaccines 
formulated with and without Salmonella proteins: PrgI, SipD and SipB; using Freund’s and MPL+AH as adjuvants 
(refer to Table 2.2). Animals were monitored for up to 14 days post challenge. 
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Flow Charts for Experiment 2, continued 
                          
Figure 2.2. 80 mice were given intranasal immunizations on days 0,14 and 28. Mice were bled 2 days prior to immunizations and 
orogastric challenge with S. typhimurium strain SL1344.  Groups of 10 mice were given vaccines formulated with and without 
Salmonella proteins: PrgI, SipD and SipB; using Cholera toxin and MPL and Chitosan + MPL as adjuvants (refer to Table 2.2). 




Flow Charts for Experiment 2, continued 
                  
Figure 2.3. 70 mice were given intramuscular immunizations on days 0,14 and 28. Mice were bled 2 days prior to 
immunizations and intranasal challenge with S. flexneri strain 2457T.  Groups of 10 mice were given vaccines formulated 
with and without Shigella proteins: MxiH, IpaD and IpaB; using Freund’s and MPL+AH as adjuvants (refer to Table 2.2). 




Flow Charts for Experiment 2, continued 
                                   
Figure 2.4. 80 mice were given intramuscular immunizations on days 0,14 and 28. Mice were bled 2 days prior to 
immunizations and intranasal challenge with S. flexneri strain 2457T.  Groups of 10 mice were given vaccines formulated with 
and without Shigella proteins: MixH, IpaD and IpaB; using Cholera toxin, MPL and Chitosan + MPL as adjuvants (refer to 
Table 2.2). Animals were monitored for up to 14 days post challenge.
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Vaccine Formulation for Experiment 2 
Vaccines for Experiment 2 were mass formulated by group in 1.5mL, sterile 
Eppendorf tubes. Tables 2.3-2.6 provide the quantities of adjuvants (listed in Table 2.2) 
used in microliters for each immunization. Amounts of each protein used at calculated 
concentrations (A=εbc) are given in microliters in these tables as well. For intramuscular 
vaccines alhydrogel (AH) was initially bound to the antigens by mixing with gentle 
agitation for 30 minutes, which ensured maximal antigen binding to Monophosphoryl 
lipid A (MPL). Vaccines formulated with these adjuvants contained 30μg of both AH and 
MPL. Freund’s complete (FCA) and Freund’s incomplete adjuvants (FA) were used for 
intramuscular immunizations and were mixed at a 1:1 ratio with antigens by pipetting 
with subsequent vortexing.  For intranasal immunizations, 1mg of cholera toxin (CT) 
adjuvant was reconstituted with 1 mL deionized water.  Reconstituted CT was then mixed 
with antigens by simple pipetting. Vaccines formulated with CT contained 2.5μg for each 
immunization. The adjuvant chitosan was used with MPL in intranasal immunizations. 
Each vaccine was formulated with 10ug of each chitosan and MPL. Chitosan was first 
vortexed into 1x histidine buffer to dissolve, prior to mixing with antigens by pipetting. 
MPL was then added and mixed by pipetting with subsequent vortexing.  
All Salmonella intramuscular immunizations containing antigens were formulated 
with 25μg PrgI, 25μg SipD, and 10μg SipB. The first three Salmonella intranasal 
immunizations were formulated with a total of 10μg PrgI, 10μg SipD and 2.5μg SipB. 
The fourth intranasal booster contained 10μg SipD and 2.5μg SipB only. 
All Shigella intramuscular immunizations containing antigens were formulated 
with 25μg MxiH, 25μg IpaD, and 10μg IpaB. Shigella intranasal immunizations 1-3 
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contained antigen amounts of 10μg MxiH, 10μg IpaD and 2.5μg IpaB. The fourth booster 
contained 10μg IpaD and 2.5μg IpaB only. The quantity of each protein (in μL) at 
calculated concentrations (mg/mL) that were used in each immunization is given in 
Tables 2.3-2.6.  PBS and histidine buffers were added as appropriately needed to bring 
each intramuscular vaccine to a final volume of 100μL. Each intranasal vaccine had a 




















Table 2.3. Quantities and concentrations of Salmonella proteins and quantities of adjuvants used in formulations of 
intramuscular vaccines. There were three rounds of immunizations which required that we purify additional SipB for rounds 
two and three. The total volume of each vaccine was 100μL.  Vaccines for each group were mass formulated in 1.5mL 
Eppendorf tubes. PBS and histidine buffers were added to complete formulation quantities to 100μL per dosage, when 
necessary.  
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1- PBS - - - - 100μL 






44μL - - - 100μL 
4-Freund’s (1)/ 
Incomplete 
Freund’s (2,3)  + 
protein 
44μL 22.3 μL 23/11.6μL 10.78 
μL 
100μL 
5-MPL+AH 30μL + 
3μL 





























Table 2.4. Quantities and concentrations of Salmonella proteins and quantities of adjuvants used in formulations of intranasal 
vaccines. There were three rounds of immunizations plus a fourth booster with only SipB and SipD. It was required to purify 
additional SipB for rounds two and three, and additional SipB and SipD for the fourth boost. The total volume of each vaccine 
was 30μL.  Vaccines for each group were mass formulated in 1.5mL Eppendorf tubes. PBS and histidine buffers were added to 
complete formulation quantities to 30μL per dose, when necessary.  
Table 2.4. Expt 2B 
Intranasal 
Immunization 1-3 - 
Salmonella 
Protein Concentration Immunization 4- Boost 
































8- PBS - - - - - - 30μL 
9-Cholera Toxin 2.5 μL - - - - - 30μL 
10-Cholera Toxin 
+ Protein 






0.3μL 2.5μL 30μL 









0.3μL 2.5μL 30μL 
13-Chitosan + 
MPL 
5μL +  
10μL 
- - - - - 30μL 
14-Chitosan + 
MPL + protein 








0.3μL 2.5μL 30μL 





















Table 2.5. Quantities and concentrations of Shigella proteins and quantities of adjuvants used in formulations of 
intramuscular vaccines are listed above. There were three rounds of immunizations. The total volume of each vaccine 
was 100μL.  Vaccines for each group were mass formulated in 1.5mL Eppendorf tubes. PBS and histidine buffers were 
added to complete formulation quantities to 100μL per dose when necessary.
Table 2.5. Expt 2C 
Intramuscular 





















1- PBS - - - - 100μL 




30μL - - - 100μL 
4- Freund’s (1)/ 
Incomplete 
Freund’s (2,3) + 
protein 
30μL 6.65μL 15.4μL 7.94μL 100μL 
5-MPL+AH 30μL + 
3μL 





6.65μL 15.4μL 7.94μL 100μL 
7-Vaccine strain-
1207 


















Table 2.6. Quantities and concentrations of Shigella proteins and quantities of adjuvants used in formulations of intranasal 
vaccines. There were three rounds of immunizations plus a fourth booster with only IpaB and IpaD. It was required to purify 
additional IpaB and IpaD for the fourth boost. The total volume of each vaccine was 30μL.  Vaccines for each group were 
mass formulated in 1.5 mL Eppendorf tubes. PBS and histidine buffers were added to complete formulation quantities to 30μL 
per dose when necessary. 




Protein Concentration Immunization 4- Boost 




























8- PBS - - - - - - 30μL 
9-Cholera 
Toxin 









0.6 μL 1.38μL 30μL 
11-MPL 10μL - - - - - 30μL 
12-MPL+ 
protein 





0.6 μL 1.38μL 30μL 
13-Chitosan + 
MPL 
5μL +  
10μL 











0.6 μL 1.38μL 30μL 









Dr. Wendy Picking completed all vaccine formulations and immunizations for 
Experiment 3.  The experimental design followed the basic procedures of Experiment 2. 
There are however several significant differences involved in the antigen/adjuvant 
combinations used. Needle proteins for Salmonella and Shigella (PrgI and MxiH 
respectively) are not used in Experiment 3. The reason for this is that these proteins 
yielded no protective value in Experiment 2. In addition to SipB and SipD, Salmonella 
protein variants of SipB were used with SipD for some of the immunizations in 
Experiment 3.These variants included SipB/SicA which stabilizes SipB, and a newly 
identified stable SipB fragment (amino acid residues 77-237). Modifications also 
included the use of fewer adjuvants in Experiment 3. Freund’s adjuvants, both complete 
and incomplete, as well as chitosan were not used in Experiment 3. These adjuvants did 
not seem to contribute to protection when immunized with antigens in Experiment 2. 
Adjuvants used in Experiment 3 are listed in Table 2.7. The less toxic, double mutant 
heat-labile toxin (dmLT) was used in place of cholera toxin. Monophosphoryl lipid A 
(MPL) was used once again along with alhydrogel (AH).  Decisions on changes made in 
Experiment 3 were loosely based on the data from Experiment 2. The overall goal of both 
experiments was to close in on an efficient antigen/adjuvant combination using the proper 
route of administration. Flow charts 2.5-2.7 depict the general process for Experiment 3, 
each chart follows the same basic procedure as Experiment 2 including: number of mice 
per group, group classification, adjuvants used, bleeding schedule, immunization days, 







Table 2.7. Adjuvants and protein amounts for Experiment 3. Antigens were formulated 
with listed adjuvants for intranasal and intramuscular immunizations for Shigella and 
Salmonella test groups by Dr. Wendy Picking. MPL and AH were used with and without 
antigens for intramuscular Shigella vaccines, rounds 1-4. Intranasal immunizations with 
and without antigens for Salmonella vaccines 1-4 were also formulated with MPL and 
AH. dmLT was used in Salmonella  intranasal immunizations for vaccine rounds 1-4.  
 
 
Table 2.7- Ex 3- Immunizations 1-4   
Adjuvants 
 Protein Amount Buffer 




IpaD 350μg His 
IpaD 600μg PBS 
SipB 200μg His Monophosphoryl 
lipid A (MPL)- 
1mg/mL SipB 300μg PBS 
SipB/SicA 200μg His 
SipB/SicA 150μg PBS Double mutant 
heat-labile toxin 
(dmLT) SipD 350μg His 
SipD 550μg PBS 
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Flow Charts for Experiment 3 
                        
Figure 2.5. 30 mice were given intramuscular immunizations on days 0,14 and 28. Mice were bled 2 days prior to 
immunizations and intranasal challenge with S. flexneri  strain 2457T.  Groups of 10 mice were given vaccines formulated 
with and without Shigella proteins: IpaD and IpaB; using MPL + AH a as adjuvants (refer to Table 2.6). Animals were 




Flow Charts for Experiment 3, continued 
                 
Figure 2.6. 50 mice were given intranasal immunizations on days 0,14 and 28. Mice were bled 2 days prior to immunizations and 
orogastric challenge with S. typhimurium strain SL1344.  Groups of 10 mice were given vaccines formulated with and without 
Salmonella proteins: SipB and SipD, SipB/SicA with SipD and SipB fragment with SipD; using MPL with alhydrogel as adjuvants 
(refer to Table 2.6). Animals were monitored for up to 14 days post challenge. 
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 Flow Charts for Experiment 3, continued 
                     
Figure 2.7. 60 mice were given intranasal immunizations on days 0,14 and 28. Mice were bled 2 days prior to immunizations 
and orogastric challenge with S. typhimurium strain SL1344.  Groups of 10 mice were given vaccines formulated with and 
without Salmonella proteins: SipB and SipD, SipB/SicA with SipD and SipB fragment with SipD; using dmLT as the adjuvant 




For Experiment 2, the animals receiving the intramuscular vaccine were given 
three immnizations every two weeks beginning with day 0. Twenty-eight days after the 
third immunization, animals were challenged with either Salmonella serovar 
Typhimurium (SL1344) or S. flexneri (2745T). Animals receiving the intranasal vaccine 
were given a fourth boost containing tip protein antigens and then subsequently 
challenged 28 days later with SL1344 and 2457T. 
All groups receiving intramuscular vaccines were immunized with a 100μL 
injection into the biceps femoris using a 1 mL syringe with a 27-gauge needle. Intranasal 
immunizations and the Shigella vaccine strain  (1207) were administered as 30μL doses. 
Immunizations were applied to nares of mice via micropipette tip. To immunize with the 
Salmonella (SL3261) vaccine strain, 100μL of the bacterial strain was given 
orogastrically by passing 20-guage bulb-tipped gavage needle through the mouth into the 
stomach. 
Vaccine Strain 
Salmonella serovar Typhimurium strain SL3261 (attenuated vaccine strain) was 
grown to mid-log phase overnight at 37°C with shaking at 100rpm in 100mL of LB.  
Bacteria were collected by centrifugation at 3200rpm.  Bacteria were then resuspended in 
1mL of 1X PBS. Absorbance of the culture was taken at a dilution of 1:100 (10μL 
bacteria in 990μL of PBS) and further diluted with PBS to reach desired A600 of 0.15. 
100μL of Salmonella serovar Typhimurium vaccine strain SL3261 was administered 
orogastrically by gavage for each vaccine round.  
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The S. flexneri vaccine strain 1207 was grown to mid-log phase overnight. 
Guanine was added to media at 37°C with shaking at 200rpm in 100mL of TSB.  Bacteria 
were collected by centrifugation at 3200rpm.  Bacteria were then resuspended in 1mL of 
1X PBS. Absorbance of bacteria was taken at dilution of 1:100 and diluted further with 
PBS to reach desired A600 of 6.6. 30μL of S. flexneri vaccine strain 1207 was 
administered intranasally for each vaccine round.  
Blood Sampling 
Blood was collected via submandibular vein lancet technique. Mice were 
manually restrained as 0.2mL of blood obtained and drip collected into 1.5mL serum 
separation tubes. The samples were centrifuged at 12,000 rpm and sera were collected 
after separation from clotted red blood cells. One hundred μL of serum was collected 
from each animal and the samples were pooled, labeled, and stored in the freezer at -20°C 
for each experimental group. The remaining 100μL was labeled and stored for each 
individual specimen. Animals were bled two days prior to each immunization to allow 
recovery from the stress.  
Challenge 
Log-fold dilution experiments were performed to determine bacterial strain 
concentration for challenge dose. One hundred-fold dilutions of bacterial strains SL1344 
and 2457T plated on LB agar and left overnight to incubate at 37°C. Colony forming 
units were quantified to determine the bacteria/mL to allow for administration of a 
uniform dose per animal.  Animals were challenged 28 days after last immunization. 
Salmonella serovar Typhimurium strain SL1344 was grown to mid-log phase 
overnight at 37°C with shaking at 100rpm in 200mL of LB.  Bacteria were collected by 
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centrifugation at 3200rpm.  Bacteria were then resuspended in 10mL of 1X PBS. 
Absorbance at 600nm was taken of bacteria at a dilution of 1:100 (10μL bacteria in 
990μL of PBS) and further diluted with PBS to reach desired A600 of 0.15. One hundred 
μL of Salmonella serovar Typhimurium vaccine strain SL1344 was administered 
orogastrically by gavage for challenge.  Animal appearance and weights were monitored 
and recorded for up to two weeks post challenge. 
S. flexneri strain 2457T was grown to mid-log phase overnight at 37°C with 
shaking at 200rpm in 200mL of TSB.  Bacteria were collected by centrifugation at 
3200rpm.  Bacteria were resuspended in 10mL of 1X PBS. Absorbance of the culture was 
taken at dilution of 1:100 (10μL bacteria in 990μL of PBS) and diluted further with PBS 
to reach desired A600 of 6.6. Thirty μL of S. flexneri vaccine strain 2457T was 
administered intranasally for challenge using the accepted mouse lung infection model. 
Monitoring 
Animals were examined for appearance twice-daily post challenge. Weights were 
recorded once daily at which time the animals were scored based on degree of sickness. 
Moribund animals were euthanized promptly by cervical dislocation as per Institutional 
Animal Care and Use Committee regulations. All surviving animals were euthanized 
after the 15
th
 day post challenge.   
Immunology 
Upon completion of vaccine trials, serum collected from animals at each 
preimmunization time-point was analyzed for immune response by enzyme-linked 
immunosorbent assay (ELISA). All ELISA’s were performed following the Standard 
Operating Procedures (SOPs) provided by the Center for Vaccine Development at the 
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University of Maryland School of Medicine. In conjunction with the SOPs, each assay 
was documented, step-by-step using the Qualitative ELISA Worksheet: AI-01. This 
template provides the basic ELISA protocol but can be individualized for each assay. The 
form also provides a place for documentation of: 1) coating of plates with antigens, 2) 
blocking of plates with 10% non-fat dry milk, 3) incubation of plates with specimens, 4) 
conjugate incubation of plates with secondary antibody, 5) binding of substrate, 6) 
addition of stop solution to end the reaction. ELISA’s for Experiments 2 and 3 were 
completed using these guidelines.  
  On day one antigens were diluted into 10mL of PBS to achieve 0.1μg/100μL. 
Ninety-six well Immulon* Immunoassy U-bottom plates were coated with antigen. Each 
well was coated with 100μL of antigen and incubated for 3 hours at 37°C.  Following 
incubation, plates were then washed 6 times with 1x PBS + 0.5% Tween. The plates were 
aspirated between each wash. Plates were coated with 10% non-fat dry milk (NFDM) 
blocking buffer in the amount of 250μL/well. Plates were incubated at 4°C overnight. 
On day two plates were washed 6 times with 1x PBS + 0.5% Tween. The plates were 
aspirated between each wash. Serum samples from previously bled mice were used as 
primary antibody. The lowest dilution for mouse serum accepted is 1:50 (Standard 
Operating Procedure provided by the Center for Vaccine Development). Five μL of 
mouse serum was diluted into 250uL 10% NFDM + 1x PBS + 0.5% Tween. Each well 
was coated with 100μL of diluted serum. Samples were laid down in pairs following pre-
determined template (Figure 2.8). Row H contained 10% NFDM + 1x PBS + 0.5% 
Tween to serve as blank for each plate. Columns 11and 12 were reserved for the standard 
control. This control is titered down the columns by beginning with 200μL of diluted 
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control in row A of columns 11 and 12. Rows B-G in columns 11 and 12 contained 
100μL of 10% NFDM + 1x PBS + 0.5% Tween. One hundred μL was taken from row A 
and diluted by mixing into row B. This 100μL dilution was followed through row G in 
columns 11 and 12.Plates were incubated for 1 hour at 37°C, and washed 6 times with 1x 
PBS + 0.5% Tween. One hundred μL of peroxidase-labeled, goat anti-mouse IgG was 
laid down on plates as secondary antibody. Each well received 100μL of secondary 
antibody at a concentration of 1mg/mL diluted 1:1000 in 10% NFDM. Plates were 
incubated for 1 hour at 37°C, and washed 6 times with 1x PBS + 0.5% Tween. Equal 
volumes of TMB Peroxidase Substrate and Peroxidase Substrate Solution B were mixed 
to form the substrate. One hundred μL of substrate was placed in each well and incubated 
on shaker at room temperature for 15 minutes, covered. One hundred μL 1M phosphoric 
acid stop solution was added to plates with bound substrate. Plates were read immediately 
on multi-scan plate reader taking the optical density at 450nm.  Values for each well were 
pasted into Qualitative ELISA regression template, provided by the Center for Vaccine 






ELISA Plate Template 
               
 
 
Figure 2.8. ELISA plate template. Template is used for each ELISA run and made before beginning assay. Row H is 












The Overall Results 
Animals immunized with the PrgI, SipD and SipD (from Salmonella) or MxiH, 
IpaD and IpaB (from Shigella) showed increasing antibody titers with each additional 
immunization.  Overall results of Experiments 2 and 3 are best presented in tables 
illustrating serum antibody titers resulting from ELISA assays for each bleed followed by 
plotting the accompanying survival rates for vaccination regimen.  These tables are 
divided into groups of mice immunized with Salmonella proteins (intramuscular and 
intranasal immunizations) and mice immunized with Shigella proteins (intramuscular and 
intranasal immunizations).  
This chapter also reports the titer values determined using ELISA’s for each 
group and each bleed.  Titer values reflect the detectable level of antibody present in the 
serum.  Titers are determined based on optical density of samples at 450nm according to 
the protocols in the previous chapter.  Results must fall between the standard control 
curves to be assigned a titer value.  Titers are used here as an assessment of the immune 
response to a given antigen.  It is assumed here that higher levels of antibodies will yield 
protection, but that cannot be verified without also determining the survival rates in 
challenge experiments. Survival curves are listed for each route of administration for both 
Salmonella and Shigella. Each curve plots survival percentage for a given group of 
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animals versus time post challenge with the final data collected by Dr. Wendy Picking. 
Salmonella Results for Experiment 2 
Results of intramuscular Salmonella vaccines are presented in Figure 3.1. Results 
show no protection using Freund’s adjuvant with Salmonella proteins PrgI, SipD, and 
SipB (I/D/B). There was 90% survival within the group immunized with 
Monophosphoryl lipid A (MPL) + Ahlydrogel (AH) + I/D/B. Mice immunized with MPL 
+ AH alone had 56% surivial within the group. Freund’s adjuvant was not anticipated to 
offer protection when immunized with I/D/B and results in Figure 3.1 confirm this. 
Protection was anticipated with the use of MPL + AH +I/D/B and the 90% survival rate 
looks promising.  The 56% survival of mice immunized with MPL + AH alone brings 
protection of the group immunized with MPL + AH +I/D/B into question, however, since 
there should be no reason for these mice to survive the challenge at this high rate.  
The titers shown in Table 3.1 reflect antibodies to SipB and SipB generated post-
ELISA at each bleed interval.  Each bleed was completed two days prior to 
immunizations.  All animals whose immunizations included I/D/B showed increasing 
antibody production by by bleed four as expected. Mice immunized with I/D/B alone had 
the lowest titers of the animals receiving antigens and these values correlated with a low 
survival rate. Titers for immunizations with Freund’s + I/D/B had the highest titers but 
the lowest of all the survival rates. Titers for the group immunized with MPL + AH 
+I/D/B displayed a modest correlation with survival.  
It is generally expected that the titers of mice immunized with I/D/B should 





     
  
Figure 3.1. Survival of mice immunized intramuscularly with Salmonella proteins: PrgI, 
SipB and SipD, Freund’s and Incomplete Freund’s with and without antigens, and MPL 







Antibody Titers for Salmonella Immunizations 
Table 3.1. Assigned titers reflecting the quantity of antibodies to SipB and SipD based on ELISA. TMB (3,3',5,5'-
tetramethylbenzidine) soluble substrate was used for enzyme catalysis of peroxidase-labeled goat anti-mouse IgG. This 
reaction yields a blue color when peroxidase is detected. The color then changes to yellow with the addition of 




they did not show strong rates of survival during the challenge.  The MPL + AH titers 
were low, as expected; however a large number (56%) of these animals survived. This 
was not expected. No titers were expected for the control group given PBS, but for an 
unknown reason, had titers beginning at bleed three.  
Results of intranasal Salmonella vaccines are presented in Figure 3.2. Mice 
immunized with cholera toxin (CT) had 50% survival. Mice given CT +I/D/B had a 60% 
survival, which is only 10% more survival than CT alone.  Mice immunized with MPL 
had a survival of 60% and mice given MPL + I/D/B had a survival of 80%. 
Immunizations with MPL + Chitosan resulted in a 40% survival within the group and this 
was greater than the survival seen for mice given MPL + Chitosan + I/D/B (10% 
survival. Titers reflect poor antibody response for this group. 
It was anticipated that groups given immunizations formulated with I/D/B would 
have substantially higher survival than those immunized without I/D/B, however, this 
was not the case. While groups given immunizations containing I/D/B had higher 
survival (excluding the MPL + Chitosan + I/D/B group) than that of their corresponding 
control groups, none were substantially higher and offer no definitive results with regard 
to vaccine efficacy.   
Titers for mice given intranasal immunizations are shown in Table 3.1. 
Antibodies to SipB and SipD generated post ELISA are evident at each bleed interval. 
All animals whose immunizations included I/D/B showed increasing titer values by bleed 
four as expected, however, these increases were not as substantial as the increases seen 
for the intramuscular immunizations. Survival of mice within groups did not appear to 








 Figure 3.2. Survival of mice immunized intranasally with Salmonella proteins: PrgI, 
SipB and SipD, Cholera toxin with and without antigens, MPL with and without antigens, 
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substantial when compared to adjuvants alone. These results are not consistent due to 
discrepancies in the survival versus the titer values. For example, based on lower titers 
than the group given MPL+ Chitosan+ I/D/B, animals given MPL+ Chitosan alone 
should not have survived, yet they did and in fact had higher survival than the group 
given MPL+ Chitosan+ I/D/B.  All other groups given immunizations with I/D/B had 
higher titers and survival than that of their controls, but none were great enough to yield 
substantial results.  
Shigella Results for Experiment 2 
Mice immunized intramuscularly with Shigella proteins did not survive the 
challenge.  There are no results of survival for this section due to the death of all groups 
of mice.  This outcome was not expected and was unfortunate.  It was assumed based on 
high titer values, that mice given immunizations with H/D/B would survive the challenge. 
The titers for mice immunized intramuscularly with Shigella proteins are listed in Table 
3.2. Titers reflect antibodies to IpaB and IpaD generated post-ELISA at each bleed 
interval.  Each bleed was completed two days prior to the subsequent immunization.  All 
animals whose immunizations included MxiH, IpaD, and IpaB (H/D/B) showed 
increasing titers by bleed four as expected, however, while titers for all animals 
immunized with H/D/B were high, there is no sign of vaccine efficacy if there is no 
survival. 
The intranasal immunizations with the Shigella proteins and cholera toxin (CT) 
provided the most substantial results for Experiment 2.  The immunizations with H/D/B  
+ (CT) were successful in providing complete (100%) protection against challenge (Fig 
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3.3). The H/D/B  + CT group antibody titers were 5,041,306.68 against IpaB and 
2,667.69 against IpaD after the fifth bleed (Table 3.2), which was anticipated and 
certainly correlates with survival in this section of the experiment. CT alone had only 
30% survival within the group, which is higher than expected but substantially lower than 
CT with the proteins. Immunizations formulated with MPL, and MPL + Chitosan with 
H/D/B did not fare well in the challenge. These results from Experiment 2 seem to 
indicate that the intranasal immunizations with Shigella proteins and CT provide 
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Figure 3.3. Survival of mice after intranasal immunizations with Shigella proteins MxiH, 
IpaB, and IpaD. The adjuvants used for immunizations included: cholera toxin with and 
without proteins; MPL with and without proteins; and Chitosan + MPL with and without 
proteins. The graph illustrates survival rate versus time. The survival rate of the mice begins 
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Shigella Results for Experiment 3 
Shigella immunizations for Experiment 3 were only done intramuscularly (see 
Figure 3.4). Animals given IM immunizations formulated with Monophosphoryl lipid A 
(MPL) + AH + IpaD and IpaB (D/B) had 60% survival within the group.  Only 10% of 
mice immunized with MPL + AH alone survived the challenge. These results are based 
upon and reinforce anticipated potential using MPL as an adjuvant for IM vaccination. 
Titers for mice immunized intramuscularly with Shigella proteins are listed in Table 3.3. 
These titers show strong antibody responses to IpaB and IpaD at each bleed interval.  
Each bleed was completed two days prior to the subsequent immunization.  All animals 
whose immunizations included IpaD and IpaB (D/B) showed increasing titer values by 
bleed four as expected. High antibody titers provide a foundation for the observed 
protection. 
Salmonella Results for Experiment 3 
In Figure 3.5 intramuscular Salmonella immunizations were formulated with 
MPL + AH alone and with SipB and SipD (B/D), with SipB/SicA and SipD (B-A/D), and 
with a SipB fragment and SipD (B-frag/D). Unfortunately, none of the mice survived the 
challenge. High titer values for the groups immunized with SipB and its variants with 
SipD did not correlate with a high rate of survival (Table 3.4). These results were not 


















Figure 3.4. Survival of mice after intramuscular immunizations with Shigella proteins: 
IpaB and IpaD with and without MPL.  
 
 
Mice immunized IM with IpaB/IpaD and Challenged with Shigella
days after challenge
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Table 3.3. Shigella antibody titers listed above reflect the quantity of antibodies to IpaB and IpaD based on ELISA  









Figure 3.5. Survival of mice immunized intramuscularly with Salmonella proteins SipB 
and SipD with and without MPL, SipB-SicA complex with MPL and SipD, SipB-
fragment and SipD with MPL. 
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Intranasal immunizations with Salmonella proteins in Figure 3.6 show mice 
immunized with the SipB-SicA complex and SipD + dmLT had a survival rate of 50%. 
No other groups had higher than 30% survival, however the group given dmLT alone had 
only 20% survival within the group. Titers for the group immunized with the SipB-SicA 
complex along with SipD + dmLT were very high against SipB at 1,280,663.67 (Table 
3.4). They were the highest titers out of all the mice in this experiment. It was expected 
that with such high titers this group would have the highest rate of survival. These results 
show promise for immunizations formulated with the SipB-SicA complex.  
Substantially high antibody titer levels for both immunization regimens in 
Experiment 3 show that immunity is developed against IpaD, IpaB, SipD and SipB. In 
addition to high titer levels, survival rates of animals immunized with with IpaD/IpaB + 
MPL+ AH and the SipB-SicA complex and SipD + dmLT had higher survival rates 
compared to any of the other groups tested. Although the Salmonella intramuscular 










Figure 3.6. Survival of mice immunized intranasally with Salmonella proteins SipB and 
SipD with and without dmLT, SipB-SicA complex with dmLT and SipD, SipB-fragment 
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Table 3.4 lists assigned titers reflecting the quantity of antibodies to SipB and SipD based on ELISA assay and optical 











Discussion and Future Directions 
The goal of Experiment 2 was to determine the effectiveness of different 
adjuvants in combination with type III secretion needle, translocator and effector proteins 
as subunit vaccines to protect against Salmonella serovar Typhimurium and Shigella 
flexneri infections. Both intranasal and intramuscular immunizations were tested to 
determine the influence that the route of administration has on protective efficacy.  PrgI, 
SipB, and SipD were used as antigens for protection against Salmonella serovar 
Typhimurium and MxiH, IpaB, and IpaD were the antigens used to protect against S. 
flexneri infection.  These proteins comprise the essential extracellular components of the 
type three-secretion apparatuses used by these pathogens. These virulence factors are 
required for invasion of host cells by these facultative intracellular pathogens. The 
adjuvants chosen for this experiment stimulate the innate and adaptive immune responses 
in different ways. Freund’s adjuvant is heat killed, dried mycobacterium components 
dispersed in a water in oil emulsion and it can potentially be toxic or cause tissue 
damage; however, it is known to be an effective adjuvant in animals immunized by the 
intramuscular route. It was only used for a primary immunization because it is known to 
be very effective in stimulating the initial immune responses in animals when co-
administered with antigens. Incomplete Freund’s adjuvant lacks the mycobacterial 
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components but continues to boost the immune system after the initial immunization for 
these animals. Monophosphoryl lipid A (MPL), is derived from the lipid A portion of 
Salmonella LPS and is known to enhance specific immunity and stimulate the synthesis 
of cytokines after recognition by toll-like receptor 4 (TLR-4). Alhydrogel (aluminum 
hydroxide) is currently approved for use in human vaccines because it is very stable, it 
readily adsorbs proteins and it rarely yields adverse effects in animals or humans.  
Cholera toxin (CT) promotes long-term mucosal immunity when used in intranasal 
vaccine formulations; however, it is not approved for use in humans due to toxicity 
issues. Nevertheless, E. coli heat-labile enterotoxin (LT) is almost identical to CT and a 
mutated derivative of LT (called dmLT). It is greatly reduced in toxicity and it may be 
promising for future use in humans for eliciting mucosal immune responses against co-
administered antigens.  Chitosan was also used as an adjuvant because it has been shown 
to stimulate cytokines that enhance the immune response while providing a nontoxic and 
natural mucosal delivery vehicle for protein antigens. Live-attenuated Salmonella and 
Shigella vaccine strains were used in these experiments as positive controls. Survival of 
these mice demonstrates antibody production to the lipopolysaccharide components of 
these strains.  
A major outcome of Experiment 2 was that it has provided a foundation upon 
which additional experiments could be developed for identifying a fully efficacious 
adjuvant/immunization combination. Only the mice immunized intranasally with Shigella 
proteins MxiH, IpaB, and IpaD formulated with CT provided complete protection against 
lethal challenge with S. flexneri 2457T. This level of protection was even better that that 
seen for a known protective live, attenuated Shigella vaccine strain. CT is known to be a 
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strong systemic and mucosal adjuvant (Vajdy and Lycke, 1992). Another encouraging 
result within Experiment 2 involved the intramuscular immunizations in which MPL and 
AH were combined with Salmonella proteins PrgI, SipD and SipB. These immunizations 
appeared to provide partial protection against Salmonella challenge. Unfortunately this 
adjuvant combination alone also provided partial protection. Although the overall result 
was inconclusive, it does provide promise that MPL and AH can be used as intramuscular 
adjuvants for anti-salmonellosis vaccines and suggests that PrgI, SipD, and/or SipB are 
effective and protective antigens.  
The data from Experiment 2 that were not successful still provided valuable 
information with respect to future direction of research. The low survival rate of the 
group immunized intramuscularly with Salmonella proteins PrgI, SipD and SipB with the 
Freund’s was somewhat surprising since the MPS plus AH adjuvnats appeared to work 
with these antigens. The intranasal vaccines formulated with MPL with PrgI, SipD and 
SipB for Salmonella could not be evaluated unfortunately due to the high survival rates of 
the negative controls (adjuvants only). In contrast, the intranasal administration of MPL 
with MxiH, IpaD and IpaB clearly offered no substantial protection against Shigella 
challenge, perhaps implying that MPL may be better served when used as an adjuvant for 
intramuscular vaccines. Chitosan was added to intranasal immunizations formulated with 
MPL and Salmonella and Shigella proteins with the expectation that it would offer 
enhanced delivery and presentation of these proteins. The low survival rate of these 
groups showed that it did not enhance protection at all. In the end, Experiment 2 only 
offered two possible vaccine insights.  First, the proteins PrgI, SipD and SipB with MPL 
and AH may provide protection against Salmonella infection when administered 
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intramuscularly. Second, MxiH, IpaD and IpaB may provide protection when 
administered intranasally with CT as the adjuvant. 
The approach of Experiment 3 focused more on the TTSS needle tip proteins as 
vaccine components rather than the needle proteins. For protection against Shigella 
infection, this meant focusing on IpaD and IpaB. In this experiment, we also focused on 
vaccinating intramuscularly for protection against shigellosis. Shigella proteins IpaB and 
IpaD were used as antigens for intramuscular immunizations. Mice immunized 
intramuscularly with MPL with AH and Shigella proteins IpaB and IpaD had 60% 
survival with high antibody titers against IpaB and IpaD. Survival of mice given MPL 
with AH alone was only 10%. These results appear to validate the use of MPL with AH 
as successful intramuscular adjuvants, and show that protection against shigellosis be 
possible with an intramuscular vaccine. 
The goal for the Salmonella immunizations in Experiment 3 was to provide a 
more stable form of the antigen that was being delivered.  This involved using the 
SipB/SicA complex along with SipD, and a SipB fragment that is known to be stable 
alone with SipD as the antigens for both intramuscular and intranasal immunizations. 
Double mutant heat-labile toxin (dmLT) was used as an intranasal adjuvant in these 
experiments instead of CT. dmLT is considered safe and effective and the mice 
immunized intranasally with the Salmonella SipB-SicA complex and SipD with dmLT 
had the greatest survival at 50%. This shows some promise for intranasal immunizations 
using the more stable SipB-SicA complex and SipD with dmLT, however, several of the 
negative control animals showed high rates of survival too (30% for PBS alone).  
76 
 
Unfortunately, the Experiment 3 intramuscular immunizations for protection 
against Salmonella challenge were not successful. It was expected that high antibody 
levels and protection would be achieved by using the adjuvants MPL and AH with the 
Salmonella proteins, however there was a high rate of death among the groups. Possible 
reasons for this may again be due to too high a challenge dose. Alternatively, lack of 
survival could be due to problems with the mouse model, since Salmonella causes a 
typhoid type of disease in mice instead of the gastroenteritis that occurs in humans.  
The dire need for a vaccine for humans against S. flexneri and Salmonella serovar 
Typhimurium infections drives research in this field. These experiments will continue 
since there is still a need for determining the optimal antigen/adjuvant combinations for 
formulating vaccines against these important enteric pathogens. The more stable 
SipB/SicA complex will be used in future experiments since it shows some early promise 
in providing protection against Salmonella challenge in mice. It may be necessary, 
however, to consider using an alternate (gastroenteritis) model for this work. Further 
work with MPL as an adjuvant is also a direction worth pursuing. Taking these initial 
steps in formulating an effective way to combat against these bacterial diseases will 
prove valuable for global public health. Though this portion of research is concluded, 
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Scope and Method of Study:  
This study focuses on the assessment of the translocators of the type III secretion 
system (TTSS) as protective antigens against Shigella and Salmonella infections 
in mice. Mice were given intramuscular and intranasal subunit vaccines 
formulated using extracellular components of the TTSA and various adjuvants. In 
Experiment 2 purified MxiH (needle), IpaD (tip protein) and IpaB (tip-associated 
translocator protein) were targeted in Shigella immunizations and in 
immunizations using purified Salmonella homologues, PrgI (needle), SipD (tip 
protein), and SipB (tip-associated translocator protein). Intramuscular 
immunizations were formulated with Freund’s adjuvant, Freund’s Incomplete 
Adjuvant, and Monophosphoryl lipid A (MPL). Intranasal immunizations were 
formulated with cholera toxin (CT), MPL and MPL with chitosan. Experiment 3 
focused on using the TTSS needle tip proteins as vaccine components. IpaB and 
IpaD were used with MPL and AH as antigens for Shigella intramuscular 
immunizations. SipB, the SipB/SicA complex, and a SipB fragment with SipD 
were used with MPL and AH in Salmonella intramuscular vaccines and with 
double mutant heat-labile toxin (dmLT) for intranasal vaccines.  Mice receiving 
Shigella vaccines were challenged intranasally with Shigella strain 2457T. Mice 
given Salmonella vaccines were challenged ororgastrically with Salmonella strain 
SL1344. Mice were monitored for up to two weeks post challenge.  
 
Findings and Conclusions:   
Experiment 2 offers two possible vaccine insights.  First, the proteins PrgI, SipD 
and SipB with MPL and AH may provide protection against Salmonella infection 
when administered intramuscularly. Second, MxiH, IpaD and IpaB may provide 
protection when administered intranasally with CT as the adjuvant. Findings for 
Experiment 3 offer further understanding by using tip proteins as vaccine 
components. IpaD and IpaB in combination with MPL and AH appear to validate 
that protection against shigellosis may be possible with an intramuscular vaccine. 
Furthermore, the Salmonella SipB-SicA complex and SipD administered 
intranasally with dmLT may provide protection against Salmonella infection. 
 
 
 
